How much lift to the UPLIFT study? - Authors' reply

The Lancet

Volumn 375, Issue 9710, 2010, Pages 198-

  Decramer, Marc ^a   Kesten, Steven ^b   Celli, Bart ^c   Tashkin, Donald P ^d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; TIOTROPIUM BROMIDE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; HUMAN; LETTER; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION;

EID: 73949132196     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60090-6     Document Type: Letter

References (2)

1. Vincken W., van Noord J.A., Greefhorst A., et al. Improvements in health status in patients with COPD during one year treatment with tiotropium. Eur Respir J 19 (2002) 209-216
2. Tashin D.P., Celli B., Senn S., et al., for the UPLIFT study investigators. A four year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008) 847-854